Clinical trials: Carcinoma of Prostate (Disorder)
Prostate Cancer
Liposomal Doxorubicin in Treating Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating patients with…
- Trial name
- NCT00004014
- Testing
- pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Case Comprehensive Cancer Center
Metastatic Prostate Cancer
64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)
This is a Phase 1 trial of TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592).
- Trial name
- CUPID (NCT04726033)
- Testing
- 64Cu-DOTA-TLX592
- Where
- 2 sites in Australia
- Volunteers
- 14 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Advanced or Metastatic Solid Tumors, Breast Cancer
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
The goal of this phase 1/2 clinical trial is to investigate the safety of an investigational drug called VIO-01 when taken by people who have different types of solid tumor cancers.
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Recurrent Ovarian Cancer, Prostate Cancer
- Trial name
- NCT06257758
- Testing
- VIO-01
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Valerio Therapeutics
Breast Carcinoma, Male Breast Carcinoma
Access to Genetic Testing in Underserved Patients With Cancer
This study compares the experiences of people who receive information about genetic testing from a computer-generated character to patients who receive information from a human genetics healthcare provider.
- Conditions
- Breast Carcinoma, Male Breast Carcinoma, Malignant Solid Neoplasm, Metastatic Prostate Carcinoma
- Trial name
- NCT06422455
- Testing
- Best Practice, Educational Intervention, Electronic Health Record Review
- Where
- 2 sites in United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Biochemical Relapse Free Survival, Complications Rates (Erectile Dysfunction, GI, GU Complications)
HDR Brachytherapy vs SABR in Early-intermediate Prostate Cancer
This is single center prospective phase 2 randomized trial aiming to compare biochemical and clinical relapse free survival and toxicity profiles of stereotactic body radiotherapy (SBRT) versus high dose rate brachytherapy (HDRB)…
- Trial name
- NCT04870567
- Testing
- Stereotactic ablative radiotherapy, High dose rate brachytherapy
- Where
- Russia
- Volunteers
- 350 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
Prostatic Neoplasms
External Beam Radiation Therapy - Target Volume
Delivery of conformal radiation therapy following radical prostatectomy is limited by the inability to define the clinical target volume (CTV).
- Trial name
- NCT00230438
- Testing
- External Beam Radiotherapy
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- University Health Network, Toronto
Neoplasms, Prostate
Quality of Life After Permanent Interstitial Iodine Seed Prostate Brachytherapy
Retrospective study to analyze Quality of life in men after iodine seed brachytherapy for localized prostate cancer
- Trial name
- NCT02652000
- Testing
- No intervention in this retrospective study
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- Kantonsspital Graubünden
Neuroendocrine Tumors, Prostate Cancer
Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging
Quantitative parameters obtained with dynamic whole body imaging using positron emission tomography (PET) can provide additional and complementary information to standard PET.
- Conditions
- Neuroendocrine Tumors, Prostate Cancer, Prostatic Neoplasms, Carcinoid Tumor
- Trial name
- NCT04017104
- Testing
- 18F-FDG PET/CT, 68Ga-DOTATOC PET/CT, 18F-DCFPyL PET/CT
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer, Prostatic Neoplasm
Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed
This is a diagnostic accuracy prospective, single-centre, open-label, single group assignment interventional study. Its aim is to evaluate the diagnostic accuracy of [68Ga]Ga-PSMA-11 PET/CT in detection of primary tumour and…
- Conditions
- Prostate Cancer, Prostatic Neoplasm, Urogenital Neoplasms, Prostatic Disease
- Trial name
- PSMA-PROSTAPET (NCT04462926)
- Testing
- [68Ga]Ga-PSMA-11 PET/CT
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Prostate Cancer
Testosterone in Treating Patients With Progressive Prostate Cancer That No Longer Responds to Hormone Therapy
RATIONALE: High doses of testosterone may be effective in killing prostate cancer cells that no longer respond to hormone therapy.
- Trial name
- NCT00006044
- Testing
- therapeutic testosterone
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045006
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer
This is an interventional, single group assignment, prospective nonrandomized, open label Phase 2 trial designed to evaluate 18F-DCFPyL PET imaging in men diagnosed with prostate cancer with increasing prostate-specific antigen…
- Trial name
- NCT04727736
- Testing
- 18F-DCFPyL
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Ashok Muthukrishnan
Prostate Cancer
Real-Time MV/kV Image Guided Radiation Therapy
In current radiation therapy, imaging (typically, cone beam CT imaging or two orthogonal X-ray projection imaging) is done for patient setup before radiation dose delivery.
- Trial name
- NCT01260909
- Testing
- Real-time kV/MV Prostate Imaging
- Sponsor
- Stanford University
Prostate Cancer
Cross-linked Hyaluronan Gel Reduces Rectal Toxicity Due to Radiation Therapy for Prostate Cancer
The primary purpose of this study is to determine if cross-linked hyaluronan gel reduces the dose of radiation delivered to the rectum and the rectal toxicity of radiotherapy for localized prostate cancer.
- Trial name
- NCT00882232
- Testing
- Cross-linked hyaluronan gel
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Cancer Center of Irvine
Infiltrating Bladder Urothelial Carcinoma, Recurrent Bladder Carcinoma
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer
This pilot clinical trial studies the side effects of recombinant EphB4-HSA fusion protein before surgery in treating patients with transitional cell carcinoma of the bladder, prostate cancer, or kidney cancer.
- Conditions
- Infiltrating Bladder Urothelial Carcinoma, Recurrent Bladder Carcinoma, Stage I Prostate Cancer, Stage I Renal Cell Cancer
- Trial name
- NCT02767921
- Testing
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Radical Cystectomy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Southern California
Prostate Cancer, Breast Cancer
Nutritional Supplements & Complementary/Alternative Medicine by Prostate & Breast Cancer Patients
This study was a survey to determine the frequency of Complementary and Alternative Medicine (CAM) use in patients recently diagnosed with breast or prostate cancer who were starting radiation therapy.
- Trial name
- NCT01823549
- Testing
- questionnaire administration
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Prostate Cancer
Evaluation of Clinical and Pathological Characteristics and Routine Treatment of Patients With Prostate Cancer
To evaluate clinical and pathological characteristics and treatment protocol and outcomes of patients with prostate cancer in 2 centers of Asyut from 2013 to 2023
- Trial name
- NCT05690399
- Testing
- Radiotherapy
- Volunteers
- 100 people
- Sponsor
- Assiut University
Diagnostic Imaging
PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers
Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY86-7548 in patients with cancer.
- Trial name
- NCT01205321
- Testing
- Bombesin (68Ga) labeled (BAY86-7548)
- Where
- 3 sites in Finland, Germany and 1 more
- Volunteers
- 19 people
- Sponsor
- Lantheus Biosciences Ltd.
Prostatic Neoplasms
Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer
This is a multi-center, open-label, Phase 1/2 study of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel and prednisone for the first-line treatment of metastatic hormone-refractory prostate cancer (mHRPC).
- Trial name
- NCT00137436
- Testing
- Docetaxel, Prednisone, SU011248
- Where
- 24 sites in United States
- Volunteers
- 93 people
- Sponsor
- Pfizer
Prostate Cancer
Utrecht Prostate Cohort for Cancer Treatment Intervention Studies and Long-term Evaluation
Rationale: Prostate cancer is the most common cancer in men worldwide. Survival rates are high due to the typically non-aggressive nature of disease and effective treatments.
- Trial name
- UPC (NCT04228211)
- Where
- 2 sites in Netherlands
- Volunteers
- 1,500 people
- Sponsor
- UMC Utrecht
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.